Nebicapone (developmental code name BIA 3-202) is a catechol O-methyltransferase (COMT) inhibitor which was under development for the treatment of Parkinson's disease but was never marketed.

[1][2] It is a nitrocatechol and is structurally related to entacapone, nitecapone, and tolcapone.

[2] The drug shows peripheral selectivity and does not significantly act in the brain.

[2] In contrast to the centrally penetrant tolcapone, nebicapone does not potentiate the psychostimulant-like effects of amphetamine in animals.

[3][4] Nebicapone was found to be effective for Parkinson's disease in clinical trials.